Ahmed Nada: Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions

Ahmed Nada, Researcher at Global Alliance of Young Researchers, shared on LinkedIn:

“Our Study titled:

‘Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis’ has been published online.

Important Highlights:

• Explored everolimus, an mTOR inhibitor, for its effect on NF-1 lesion size via meta-analysis.

• Four phase II single arm trials with 83 patients showed no significant effect of oral everolimus on lesion size reduction.

• Safety discrepancies across studies raise concerns about everolimus’ overall safety in NF-1 patients.

• Emphasizes the necessity for more research, personalized treatments, and larger standardized trials in NF-1.

you can read the full text here.

Thanks to Global Alliance of Young Researchers, Mostafa Meshref , and Abdulqadir Nashwan for their great efforts.”

Source: Ahmed Nada/LinkedIn